Business
Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance rolled forward to +5-6% cc CAGR for 2025-2030, following upgrade of 2024-2029 guidance to +6% cc1Peak sales guidance upgraded for Kisqali and Scemblix; Novartis now has eight de-risked, in-market assets with USD 3-10 billion peak sales potential15+ potentially submission-enabling readouts expected in the next two years to fuel long-term growth Pipeline includes 30+ potential high-value medicines, with 10+ licensed or acquired in
About this update from Novartis Ag
[{"type":"image","alt":"Novartis Pharma AG","displaySize":"","headline":null,"caption":"Novartis Pharma AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":287,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/838a2f0cbe482ce95bb28a161721a308"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jVHT.jc1r.9_PBg7JQVa4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/838a2f0cbe482ce95bb28a161721a308","width":287,"height":55}},"lazy":false},{"type":"text","content":"Ad hoc announcement pursuant to Art. 53 LR","length":42,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Mid-term sales guidance rolled forward to +5-6% cc CAGR for 2025-2030, following upgrade of 2024-2029 guidance to +6% cc1","length":121,"tagName":"p"}]},{"val":[{"type":"text","content":"Peak sales guidance upgraded for Kisqali and Scemblix; Novartis now has eight de-risked, in-market assets with USD 3-10 billion peak sales potential","length":148,"tagName":"p"}]},{"val":[{"type":"text","content":"15+ potentially submission-enabling readouts expected in the next two years to fuel long-term growth ","length":100,"tagName":"p"}]},{"val":[{"type":"text","content":"Pipeline includes 30+ potential high-value medicines, with 10+ licensed or acquired in the past two years","length":105,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":474,"olType":false},{"type":"text","content":"Basel, November 20, 2025 – Novartis today rolled forward its mid-term guidance to 2025-2030 with a sales CAGR of +5-6% cc. The updated outlook will be featured at its Meet Novartis Management event in London today and reflects continued strong momentum from in-market growth drivers and upcoming launches, most with issued US patent protection throughout the 2030s.","length":365,"tagName":"p"},{"type":"text","content":"Higher peak sales guidance for key brands reinforces confidence in the company’s mid-term outlook:","length":98,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Kisqali raised from USD 8 billion+ to USD 10 billion+","length":53,"tagName":"p"}]},{"val":[{"type":"text","content":"Scemblix raised from USD 3 billion+ to USD 4 billion+","length":53,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":106,"olType":false},{"type":"text","content":"Novartis now has eig...